Mark A Fiala1, Soo Park2, Michael Slade2, John F DiPersio2, Keith E Stockerl-Goldstein2. 1. Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri. mfiala@DOM.wustl.edu. 2. Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, Missouri.
Abstract
BACKGROUND: The need to repeat peripheral blood (PB) stem cell mobilization and collection in healthy donors arises infrequently but may be required due to insufficient initial collection, graft failure, or relapse of the recipient's disease. Little data exist on the efficacy of remobilization. Therefore, we retrospectively reviewed 18 years of remobilization records from healthy stem cell donors at our institution. STUDY DESIGN AND METHODS: We identified 62 healthy donors who underwent remobilization, a cohort of 30 mobilized and remobilized with cytokines and a cohort of 32 mobilized with a CXCR4 antagonist and remobilized with cytokines. For each cohort we compared the PB CD34+/L level, the number of CD34+ cells collected/kg (recipient weight), and the number of CD34+ cells/L collected on the first day of leukapheresis during initial mobilization and remobilization. RESULTS: Initial mobilization with cytokines was associated with reduced remobilization. The mean PB CD34/L level at initial mobilization was 69 × 10(6) compared to 37 × 10(6) at remobilization (p = 0.029). In contrast, initial mobilization with a CXCR4 antagonist was not associated with reduced remobilization. The mean PB CD34/L level at initial mobilization was 15 × 10(6) compared to 68 × 10(6) at remobilization (p < 0.001). In both cohorts, initial mobilization results were positively correlated with remobilization results but the interval between was not. CONCLUSIONS: This study suggests that poor remobilization yields may be due to decreased efficacy of cytokines after repeat exposure. The underlying mechanism of these findings remains unclear and further studies are needed.
BACKGROUND: The need to repeat peripheral blood (PB) stem cell mobilization and collection in healthy donors arises infrequently but may be required due to insufficient initial collection, graft failure, or relapse of the recipient's disease. Little data exist on the efficacy of remobilization. Therefore, we retrospectively reviewed 18 years of remobilization records from healthy stem cell donors at our institution. STUDY DESIGN AND METHODS: We identified 62 healthy donors who underwent remobilization, a cohort of 30 mobilized and remobilized with cytokines and a cohort of 32 mobilized with a CXCR4 antagonist and remobilized with cytokines. For each cohort we compared the PB CD34+/L level, the number of CD34+ cells collected/kg (recipient weight), and the number of CD34+ cells/L collected on the first day of leukapheresis during initial mobilization and remobilization. RESULTS: Initial mobilization with cytokines was associated with reduced remobilization. The mean PB CD34/L level at initial mobilization was 69 × 10(6) compared to 37 × 10(6) at remobilization (p = 0.029). In contrast, initial mobilization with a CXCR4 antagonist was not associated with reduced remobilization. The mean PB CD34/L level at initial mobilization was 15 × 10(6) compared to 68 × 10(6) at remobilization (p < 0.001). In both cohorts, initial mobilization results were positively correlated with remobilization results but the interval between was not. CONCLUSIONS: This study suggests that poor remobilization yields may be due to decreased efficacy of cytokines after repeat exposure. The underlying mechanism of these findings remains unclear and further studies are needed.
Authors: R Goterris; J C Hernández-Boluda; A Teruel; C Gómez; M J Lis; M J Terol; M Tormo; C Solano; C Arbona Journal: Bone Marrow Transplant Date: 2005-11 Impact factor: 5.483
Authors: Kristina Hölig; Michael Kramer; Frank Kroschinsky; Martin Bornhäuser; Thilo Mengling; Alexander H Schmidt; Claudia Rutt; Gerhard Ehninger Journal: Blood Date: 2009-08-07 Impact factor: 22.113
Authors: Y Gazitt; C O Freytes; N Callander; T W Tsai; M Alsina; J Anderson; L Holle; J Cruz; P Devore; M McGrath; G West; R Alvarez; W Montgomery Journal: J Hematother Date: 1999-04
Authors: Neal Flomenberg; Steven M Devine; John F Dipersio; Jane L Liesveld; John M McCarty; Scott D Rowley; David H Vesole; Karin Badel; Gary Calandra Journal: Blood Date: 2005-05-12 Impact factor: 22.113
Authors: G Calandra; J McCarty; J McGuirk; G Tricot; S-A Crocker; K Badel; B Grove; A Dye; G Bridger Journal: Bone Marrow Transplant Date: 2007-11-12 Impact factor: 5.483
Authors: Iskra Pusic; Shi Yuan Jiang; Scott Landua; Geoffrey L Uy; Michael P Rettig; Amanda F Cashen; Peter Westervelt; Ravi Vij; Camille N Abboud; Keith E Stockerl-Goldstein; Diane S Sempek; Angela L Smith; John F DiPersio Journal: Biol Blood Marrow Transplant Date: 2008-09 Impact factor: 5.742
Authors: Sandhya R Panch; Brent Logan; Jennifer A Sees; Stephanie Bo-Subait; Bipin Savani; Nirali N Shah; Jack W Hsu; Galen Switzer; Hillard M Lazarus; Paolo Anderlini; Peiman Hematti; Dennis Confer; Michael A Pulsipher; Bronwen E Shaw; David F Stroncek Journal: Transplant Cell Ther Date: 2021-03-09
Authors: Jingyu Xiang; Min Shi; Mark A Fiala; Feng Gao; Michael P Rettig; Geoffrey L Uy; Mark A Schroeder; Katherine N Weilbaecher; Keith E Stockerl-Goldstein; Shamim Mollah; John F DiPersio Journal: Blood Adv Date: 2022-04-12